Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of ($0.03), $0.08 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $41.3 million versus the consensus estimate of $43.92 million.

Sees Q4 combined net product sales from both HETLIOZ and Fanapt $42 to $48 million

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.